DRAFT
Patent Lens > Technology Landscapes > Agrobacterium-mediated transformation of plants

Inhibition of Agrobacterium-induced necrosis - actual pending claims

Patent application filed by Novartis

Actual pending claims

EP 986 299 A2

Claim 1

A method of transforming a plant cell with a gene of interest, comprising

  • exposing said plant cell to Agrobacterium under conditions which inhibit Agrobacterium-induced necrosis (AIN), wherein
    said Agrobacterium comprises a vector comprising said gene of interest.
Claim 8

A method of making a fertile, transgenic plant comprising: A) transforming plant tissue by exposing the tissue to Agrobacterium under conditions which inhibit Agrobacterium- induced necrosis (AIN); and
B) regenerating tissue thus transformed, wherein said Agrobacterium comprises a vector comprising a gene of interest.

Claim 9

A plant, plant tissue or plant cell comprising a nucleotide sequence of heterologous origin which inhibits AIN.

Claim 10

A plant cell or tissue culture medium, comprising:
A) a chemical inhibitor of AIN;
B) an Agrobacterium comprising a plasmid comprising a gene of interest; and
C) water and essential salts.

Claim 11

A method of transforming a totipotent cell of a plant of the family Gramineae, comprising

  • exposing a population of said totipotent cells to Agrobacterium comprising a plasmid comprising a gene of interest, wherein
    the Agrobacterium is of a strain which does not induce significant levels of necrosis in said population at an exposure duration and concentration sufficient to achieve transformation of said cell.
Claim 12

A method for determining the suitability of an Agrobacterium strain for use in the transformation of a regenerable cell of a plant of the family Gramineae comprising: A) exposing a population of said regenerable cells of the plant to the Agrobacterium strain; and
B) observing the necrosis in said cell population.

Claim 13

An Agrobacterium strain which has been genetically modified to reduce or eliminate expression of the Agrobacterium necrosis factor or a derivative of such a modified strain.

The information contained in this page was believed to be correct at the time it was collated. New patents and patent applications, altered status of patents, and case law may have resulted in changes in the landscape. CAMBIA makes no warranty that it is correct or up to date at this time and accepts no liability for any use that might be made of it. Corrections or updates to the information are welcome. Please send an email to info@bios.net.

Comments (0)